Last €36.09 EUR
Change Today -0.451 / -1.23%
Volume 44.0
GS7A On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 11:34 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GS7A) Snapshot

Open
€36.03
Previous Close
€36.54
Day High
€36.91
Day Low
€35.49
52 Week High
02/21/14 - €41.50
52 Week Low
08/11/14 - €33.72
Market Cap
87.5B
Average Volume 10 Days
675.0
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
08/6/14
P/E TM
--
Dividend
€2.56
Dividend Yield
5.35%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GS7A)

glaxosmithkline plc-spon adr (GS7A) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc-spon adr (GS7A) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GS7A) Key Developments

GlaxoSmithKline Receives FDA Approval of an Additional Promacta(R) Indication for Use in Patients with Severe Aplastic Anaemia

GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta(R) (eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST). SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets. Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells. The approval by the FDA is based on results from an investigator-sponsored Phase II study (09-H-0154) conducted by the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH). The study demonstrated a haematologic response in SAA patients treated with eltrombopag who had an insufficient response to IST: 40% (95% CI, 25, 56) of patients (N=17) experienced a haematologic response in at least one lineage -- platelets, red blood cells (RBC), or white blood cells (ANC) -- after Week 12. In the extension phase, eight patients achieved a multi-lineage response; four of these patients subsequently tapered off treatment and maintained the response (median follow up 8.1 months, range 7.2-10.6 months). 91% of patients were platelet transfusion-dependent at baseline; the platelet transfusion-free period in responders ranged from eight to 1,096 days (median 200 days). 86% of patients were RBC-transfusion dependent at baseline; the RBC transfusion-free period in responders ranged from 15 to 1,082 days (median 208 days). In the single-arm, single-centre, open-label Phase II 09-H-0154 study, eltrombopag was evaluated in 43 patients with SAA who have had an insufficient response to at least one prior IST and who had a platelet count

GlaxoSmithKline plc Receives FDA Approval for Arnuity(TM) Ellipta(R)

GlaxoSmithKline plc announced that the FDA has approved Arnuity(TM) Ellipta(R) (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm. The approved doses are Arnuity Ellipta 100mcg and 200mcg. Arnuity Ellipta is administered once daily via the dry powder inhaler called Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio.

Pernix Therapeutics Holdings, Inc., GlaxoSmithKline plc - M&A Call

To discuss the acquisition of Treximet

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GS7A:GR €36.09 EUR -0.451

GS7A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $143.94 USD -0.66
Amgen Inc $137.83 USD +0.56
AstraZeneca PLC 4,449 GBp -18.50
Bayer AG €101.51 EUR -1.15
Novo Nordisk A/S kr259.40 DKK +0.60
View Industry Companies
 

Industry Analysis

GS7A

Industry Average

Valuation GS7A Industry Range
Price/Earnings 14.4x
Price/Sales 2.7x
Price/Book 11.0x
Price/Cash Flow 14.3x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.